Point72 Asset Management
OBIO icon

Point72 Asset Management’s Orchestra BioMed OBIO Stock Holding History

Point72 Asset Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-87,888
Closed -$374K – 4428
2026
Q1 		$374K Sell
87,888
-74,058
-46% -$315K ﹤0.01% 3268
2025
Q4 		$672K Buy
+161,946
New +$653K ﹤0.01% 3083

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Point72 Asset Management's OBIO Position: Q2 2026 in Review

Point72 Asset Management sold out of Orchestra BioMed (OBIO) in Q2 2026, closing a stake of 87,888 shares — an estimated $374K sold.

Point72 Asset Management first reported a position in OBIO in Q4 2025 and held it in 2 quarters. The position peaked at $672K in Q4 2025. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Point72 Asset Management reported no remaining Orchestra BioMed position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 87,888 Orchestra BioMed shares in Q2 2026, an estimated $374K.
  • Point72 Asset Management first reported a position in Orchestra BioMed in Q4 2025 and held it in 2 quarters.
  • Point72 Asset Management's Orchestra BioMed position peaked at $672K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.